Promacta® (eltrombopag) – First-time generic

- On May 14, 2025, Camber launched an AB-rated generic version of Novartis' Promacta (eltrombopag) tablets and packets for oral suspension.

- Promacta is approved for the following indications:

    - Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
    - Treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy
    - In combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia
    - Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

- Promacta carries a boxed warning for risk for hepatic decompensation in patients with chronic hepatitis C and risk of hepatotoxicity.